179 related articles for article (PubMed ID: 36551908)
1. HCV Infection and Liver Cirrhosis Are Associated with a Less-Favorable Serum Cholesteryl Ester Profile Which Improves through the Successful Treatment of HCV.
Weigand K; Peschel G; Grimm J; Müller M; Höring M; Krautbauer S; Liebisch G; Buechler C
Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551908
[No Abstract] [Full Text] [Related]
2. Sex-specific changes in triglyceride profiles in liver cirrhosis and hepatitis C virus infection.
Peschel G; Grimm J; Müller M; Höring M; Krautbauer S; Weigand K; Liebisch G; Buechler C
Lipids Health Dis; 2022 Oct; 21(1):106. PubMed ID: 36280840
[TBL] [Abstract][Full Text] [Related]
3. Gender-Specific Differences in Serum Sphingomyelin Species in Patients with Hepatitis C Virus Infection-Sphingomyelin Species Are Related to the Model of End-Stage Liver Disease (MELD) Score in Male Patients.
Peschel G; Weigand K; Grimm J; Müller M; Krautbauer S; Höring M; Liebisch G; Buechler C
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176109
[TBL] [Abstract][Full Text] [Related]
4. Quantification of Cholesterol and Cholesteryl Ester by Direct Flow Injection High-Resolution Fourier Transform Mass Spectrometry Utilizing Species-Specific Response Factors.
Höring M; Ejsing CS; Hermansson M; Liebisch G
Anal Chem; 2019 Mar; 91(5):3459-3466. PubMed ID: 30707563
[TBL] [Abstract][Full Text] [Related]
5. Serum Ceramide Species Are Associated with Liver Cirrhosis and Viral Genotype in Patients with Hepatitis C Infection.
Höring M; Peschel G; Grimm J; Krautbauer S; Müller M; Weigand K; Liebisch G; Buechler C
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077197
[TBL] [Abstract][Full Text] [Related]
6. Serum omentin-1 is correlated with the severity of liver disease in patients with chronic hepatitis C.
Peschel G; Weigand K; Grimm J; Müller M; Buechler C
World J Hepatol; 2023 Dec; 15(12):1315-1324. PubMed ID: 38223417
[TBL] [Abstract][Full Text] [Related]
7. Chemerin Is a Valuable Biomarker in Patients with HCV Infection and Correlates with Liver Injury.
Peschel G; Grimm J; Gülow K; Müller M; Buechler C; Weigand K
Diagnostics (Basel); 2020 Nov; 10(11):. PubMed ID: 33228201
[TBL] [Abstract][Full Text] [Related]
8. Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C.
Jiang X; Vouri SM; Diaby V; Lo-Ciganic W; Parker R; Park H
J Manag Care Spec Pharm; 2021 Oct; 27(10):1388-1402. PubMed ID: 34595949
[No Abstract] [Full Text] [Related]
9. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients.
Beig J; Orr D; Harrison B; Gane E
Liver Transpl; 2018 Aug; 24(8):1031-1039. PubMed ID: 29577581
[TBL] [Abstract][Full Text] [Related]
12. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
13. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
Bailly F; Pradat P; Virlogeux V; Zoulim F
Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study.
Ferrarese A; Germani G; Gambato M; Russo FP; Senzolo M; Zanetto A; Shalaby S; Cillo U; Zanus G; Angeli P; Burra P
World J Gastroenterol; 2018 Oct; 24(38):4403-4411. PubMed ID: 30344424
[TBL] [Abstract][Full Text] [Related]
15. Enhanced immune responses, PI3K/AKT and JAK/STAT signaling pathways following hepatitis C virus eradication by direct-acting antiviral therapy among Egyptian patients: a case control study.
Ramadan HK; Badr G; Ramadan NK; Sayed A
Pathog Dis; 2021 Mar; 79(3):. PubMed ID: 33524139
[TBL] [Abstract][Full Text] [Related]
16. Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis.
Tmu N; Kumar A; Sharma P; Singla V; Bansal N; Arora A
J Clin Exp Hepatol; 2019; 9(1):4-12. PubMed ID: 30765933
[TBL] [Abstract][Full Text] [Related]
17. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
[TBL] [Abstract][Full Text] [Related]
18. Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection.
Salama II; Raslan HM; Abdel-Latif GA; Salama SI; Sami SM; Shaaban FA; Abdelmohsen AM; Fouad WA
World J Hepatol; 2022 Jun; 14(6):1053-1073. PubMed ID: 35978668
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
[TBL] [Abstract][Full Text] [Related]
20. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]